1. Scope and Purpose of the Project
===================================

The purpose of the present project was twofold. The first objective was to record the infrared absorption spectra of a variety of acetylated aldopyranosides for use in the identification of supposedly identical samples. The spectra of three of the compounds included in the present study were recorded by Kuhn \[[@b1-jresv64an5p405_a1b]\][1](#fn1-jresv64an5p405_a1b){ref-type="fn"} for a limited range (1,250 to 667 cm^−1^). In the following year, the spectra of 13 of the compounds were given (for the range of 5,000 to 667 cm^−1^) by Isbell and coworkers in a privately circulated report \[[@b2-jresv64an5p405_a1b]\] which was subsequently published 13\]. Twelve of the spectra obtained by these investigators were later discussed by Whistler and House \[[@b4-jresv64an5p405_a1b]\], who noted certain bands in the range of 1,205 to 855 cm^−1^. Next, Barker and coworkers \[[@b5-jresv64an5p405_a1b]\] examined the spectra of two of Kuhn's compounds and of four others that are included in the present study, but have not published them in sufficient detail to permit comparison over a wide spectral range; some of the bands in the range of 960 to 730 cm^−1^ were discussed. In the present article, the infrared absorption spectra of 24 acetylated aldopyranosides, in the range of 5,000 to 250 cm^−1^, are given; all of the bands of all of these compounds have been measured and have received consideration.

The second objective was the discovery of correlations that might be of value in structural analysis, both as regards (a) the presence of certain functional groups and (b) the particular conformation assumed by each compound. Isbell and coworkers \[[@b3-jresv64an5p405_a1b]\] recorded the infrared spectra of 13 of the compounds dissolved in suitable solvents, and were able to reach certain conclusions regarding correlations of the kind mentioned. However, at the low concentrations they employed, minor bands were absent or difficult to detect. The spectrograms have now been recorded for the solid phase, as pellets consisting of crystalline material suspended in an alkali-metal halide. \[Such spectra show more bands than those for the same compounds dissolved in a solvent. This is because, for the solid, the following factors are operative: (1) A removal of degeneracies by perturbations from lattice forces; (2) occurrence of combination vibrations between molecular and lattice modes in the solid; and (3) an intensification of overtones and combination vibrations.\]

In part II of this series of articles \[[@b6-jresv64an5p405_a1b]\], a method was described for gaining information regarding the conformations of unsubstituted aldopyranosides from analysis of their infrared spectra. The analysis revealed groups of absorption bands, characteristic for each group-configuration, which displayed a concerted shift on change of anomeric disposition. This empirical observation was employed, in conjunction with a consideration of instability factors (arrived at on theoretical grounds), in making conformational assignments and in deciding the arrangement of groups (e.g., axial or equatorial) at the anomeric carbon atom of these and related compounds. The results were essentially in agreement with those obtained experimentally by Reeves \[[@b7-jresv64an5p405_a1b]\] from a study of the behavior of these unsubstituted aldopyranosides on forming complexes with the cuprammonium reagent. The present article describes the results obtained on applying the same kind of analysis to the infrared spectra of the fully acetylated derivatives of 17 of the alclopyranosides studied in part II and of 7 acetylated aldopyranosides whose unacetylated parents were not included therein.

2. Compounds Investigated
=========================

[Table 1](#t1-jresv64an5p405_a1b){ref-type="table"} gives a list of the compounds, their code numbers \[[@b8-jresv64an5p405_a1b]\], and an index to the spectrograms; the serial number of a compound is the same as the number of its spectrogram. Also included in [table 1](#t1-jresv64an5p405_a1b){ref-type="table"} are (a) the conformation (where known) of the corresponding unacetylated glycoside, as determined in the preceding paper in this series \[[@b6-jresv64an5p405_a1b]\], and (b) assignments of conformations to the acetylated glycosides. The conformations are indicated by the system devised by Isbell and Tipson \[[@b9-jresv64an5p405_a1b], [@b10-jresv64an5p405_a1b]\].

The spectra were measured in the region of 5,000 to 667 cm^−1^ (sodium chloride optics) and in the region of 667 to 250 cm^−1^ (cesium bromide optics). The spectrograms are given together with a discussion of (a) the structure of the compounds and (b) some of the outstanding features of their spectra.

All of the compounds listed in [table 1](#t1-jresv64an5p405_a1b){ref-type="table"} are fully acetylated glycosides of aldoses, and all have the pyranoid ring. As a common structural feature, all but one of the glycosides have a glycosidic methoxyl group; one has a glycosidic cyclohexyloxy group. The acetylated glycosides differ in regard to one or more of the following structural features: (a) The *α* or *β* anomeric configuration at carbon atom 1; (b) the configurations of the other carbon atoms of the pyranoid ring (including C5 in the hexosides and heptosides); (c) the nature of the substituent, if any, at C5 (including the configuration at C6 of the heptosides); and (d) the nature of the substituent at the C-4 and C-6 hydroxyl groups.

3. Reference Aldopymnosides (of Known Conformation) and Their Acetates
======================================================================

In part II of this series, the stable conformation of each of 21 aldopyranosides was deduced from an analysis of the respective infrared absorption spectrum, and was found to be in agreement with the assignment reached from a consideration of instability factors.

In the present study, the crystalline, fully acetylated derivatives of 17 of these aldopyranosides were available (group A). In addition, 7 acetylated aldopyranosides (group B) whose unacetylated relatives had not been available (in the crystalline form) were examined. The spectra of the compounds comprising group A were analyzed, in order to determine if they were explicable on the basis that the acetate of a glycoside has the same conformation as its parent, unacetylated glycoside. The conclusions drawn from this study were then applied to deducing the stable conformation of members of group B.

4. Classification of the Acetylated Glycosides Into Configurationally Related Groups
====================================================================================

The 24 compounds were classified into three groups; the members of each group have like configurational features.

4.1. Acetylated Aldopyranosides of the *xylo* Configuration
-----------------------------------------------------------

The members of this group of acetylated methyl aldopyranosides have the following general formula (I) for the CA conformation.
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Compounds 1 to 5, in this conformation, have the above general structure, with the following substituents. 1.Methyl *α*-[d]{.smallcaps}-xylopyranoside triacetate, R=H; R′ = H; and R″=OCH~3~.2.Methyl *β*-[d]{.smallcaps}-xylopyranoside triacetate, R=H; R′ = OCH~3~; and R″ = H.3.Methyl *α*-[d]{.smallcaps}-glucopyranoside tetraacetate, R = CH~2~OAc; R′=H; and R″ = OCH~3~.4.Methyl *β*-[d]{.smallcaps}-glucopyranoside tetraacetate, R =CH~2~OAc; R′ = OCH~3~; and R″ = H.5.Methyl *β*-[d]{.smallcaps}-glucopyranosyl-(l→6)-*β*-[d]{.smallcaps}-glucopyranoside heptaacetate, R=tetra-*O*-acetyl-*β*-[d]{.smallcaps}-glucopyranosyl-OH~2~C; R′ = OCH~3~; and R″=H.

Compound 6, if it is the *β* anomer, has the following formulas (II) for the two chair-conformations.
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1.  Methyl [d]{.smallcaps}-*glycero-β*-[d]{.smallcaps}-*ido*-heptopyranoside pentaacetate

4.2. Acetylated Aldopyranosides of the *lyxo* Configuration
-----------------------------------------------------------

Six of the members of this group of configurationally related compounds have the [d]{.smallcaps}-*lyxo* or [d]{.smallcaps}-*manno* configuration and the following general formula (III) for the CA conformation.
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Compounds 7, 8, 11, 12, 14, and 15, in this conformation, have the above general structure, with the following substituents. 7.Methyl *α*-[d]{.smallcaps}-lyxopyranoside triacetate, R = H; R′ = H; R″ = OCH~3~; and R‴=Ac.8.Methyl *β*-[d]{.smallcaps}-lyxopyranoside triacetate, R = H; R′ = OCH~3~; R″=H; and R‴=Ac.11.Methyl *α*-[d]{.smallcaps}-mannopyranoside tetraacetate, R = CH~2~OAc; R′=H; R″ = OCH~3~; and R‴ = Ac.12.Methyl *β*-[d]{.smallcaps}-mannopyranoside tetraacetate, R = CH~2~OAc; R′= OCH~3~; R″ = H; and R‴=Ac.14.Methyl *β*-[d]{.smallcaps}-glucopyranosyl-(l→4)-*α*-[d]{.smallcaps}-mannopyranoside heptaacetate, R = CH~2~OAc; R′=H; R″=OCH~3~; and R‴=tetra-*O*-acetyl-*β*-[d]{.smallcaps}-glucopyranosyl.15.Methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*β*-[d]{.smallcaps}-mannopyranoside heptaacetate, R = CH~2~OAc; R′ = OCH~3~; R″=H; and R‴ = tetra-*O*-acetyl-*β*-[d]{.smallcaps}- glucopyranosyl.

Compounds 9, 10, and 13 have the [l]{.smallcaps}-*manno* configuration and the following general formula (IV) for the CA conformation.
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1.  Methyl 6-deoxy-*α*-[l]{.smallcaps}-mannopyranoside triacetate, R = CH~3~; R′=OCH~3~; and R″=H.

2.  Methyl 6-deoxy-*β*-[l]{.smallcaps}-mannopyranoside triacetate, R = CH~3~; R′=H; and R″=OCH~3~.

3.  

Compounds 16 to 19 have the [d]{.smallcaps}-*gulo* configuration and the following general formula (V) for the CA o nfo rmation.
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1.  Methyl *α*-[d]{.smallcaps}-gulopyranoside tetraacetate, R = CH~2~OAc; R′ = H; and R″ = OCH~3~.

2.  

3.  

4.  

4.3. Acetylated Aldopyranosides of the *arabino* Configuration
--------------------------------------------------------------

The CE conformation of compound 20 and the CA conformation of compounds 22 and 23 are depicted in general formula VI.
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1.  Methyl *β*-[l]{.smallcaps}-arabinopyranoside triacetate, R = H; R′=H; and R″ = OCH~3~.

2.  Methyl *α*-[d]{.smallcaps}-galactopyranoside tetraacetate, R = CH~2~OAc; R′=H; and R″ = OCH~3~.

3.  Methyl *β*-[d]{.smallcaps}-galactopyranoside tetraacetate, R = CH~2~OAc; R′=OCH~3~; and R″ = H.

The CA conformation of compound 21 and the CE conformation of compound 24 are depicted in general formula VII.
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1.  Methyl 6-deoxy-*α*-[l]{.smallcaps}-galactopyranoside triacetate, R = H; R′ = CH~3~; and R″=Ac.

2.  Methyl *β*-[d]{.smallcaps}-galactopyranosyl-(1→4)-*β*-[d]{.smallcaps}-altropyranoside heptaacetate, R=CH~2~OAc; R′=H; and R″ = tetra-*O*-acetyl-*β*-[d]{.smallcaps}-galactopyranosyl.

5. Discussion of the Spectra
============================

In the present study, the positions of the various absorption bands for each of 24 acetylated aldopyranosides have been determined; the relative intensities of absorption were not examined in detail. The bands were compiled, and were studied by statistical and comparative methods, as previously described \[[@b11-jresv64an5p405_a1b]\].

The conformations of 17 of the corresponding *unacetylated* glycosides had previously been assigned by us \[[@b6-jresv64an5p405_a1b]\] from a study of their infrared absorption spectra (see [table 1](#t1-jresv64an5p405_a1b){ref-type="table"}). Assignment was made on the basis of the empirical observation that, for the aldopentopyranosides and for members of any one group- configuration of the 5-*C*-substituted aldopentopyranosides, a change of anomeric disposition was accompanied by a concerted shift of certain groups of absorption bands.

The same kind of examination has now been applied to the spectra of the fully acetylated derivatives of these 17 aldopyranosides. A similar effect was observed, namely, that certain groups of absorption bands show a concerted shift on change of anomeric disposition. Assignments were then made, on the basis of this empirical observation, for 15 of the acetylated derivatives, and were found to be in agreement with those previously made for the unacetylated relatives. Consequently, compounds 3 and 4 were assigned the CA conformation, which had previously been inferred for their parent glycosides \[[@b6-jresv64an5p405_a1b]\].

The remaining seven spectra were those of acetylated glycosides whose parent glycosides had received no conformational assignment. Intercomparison of the spectra of four of these acetates (compounds 12 to 15, [table 1](#t1-jresv64an5p405_a1b){ref-type="table"}) with those of related acetates (especially in regard to the characteristic, anomer- differentiating absorption bands) was then under taken. For lack of spectra of related acetates, assignments could not be made for the remaining three compounds (see [table 1](#t1-jresv64an5p405_a1b){ref-type="table"}; compounds 5, 6, and 24).

5.1. Absorption Bands Possibly Indicative of the Disposition of Groups at the Anomeric Carbon Atom of the Methyl Tri-*O*-acetyl-aldopentopyranosides
----------------------------------------------------------------------------------------------------------------------------------------------------

As the starting point in these analyses, we selected methyl tri-*O*-acetyl-*β*-[d]{.smallcaps}-xylopyranoside (compound 2) because, if this compound adopts a chair conformation, the reference groups will either be all axial (CE) or all equatorial (CA). Its spectrum was compared with that of its *a* anomer (compound 1), in order to determine the effect, on the spectrum, of changing the anomeric group from equatorial to axial, or vice versa. A comparison was then made with the spectrum of methyl tri-*O*-acetyl-*β*-[l]{.smallcaps}-arabinopyranoside (compound 20).

Bands that are essentially the same for these three compounds are given[2](#fn2-jresv64an5p405_a1b){ref-type="fn"} in [table 2](#t2-jresv64an5p405_a1b){ref-type="table"}. It seemed reasonable to assume tentatively that bands shown by *all* of these acetylated glycosides might be independent of total configuration, whereas those shown by one pair of anomers (*e.g*., compounds 1 and 2) having the same group-configuration might be a reflection, *via* shifting of bands, of an effect of the configuration of that pair.

In [table 3](#t3-jresv64an5p405_a1b){ref-type="table"} are given the bands shown by *one* anomer (but not by the other) of the methyl tri-*O*- acetyl-[d]{.smallcaps}-xylopyranosides and by methyl tri-*O*-acetyl- *β*-[l]{.smallcaps}-arabinopyranoside. If the "anomer-differentiating" bands have any relationship to the axial or equatorial disposition of the respective glycosidic methoxyl group, the results in [table 3](#t3-jresv64an5p405_a1b){ref-type="table"} clearly indicate that compounds 1 and 20 have the same anomeric disposition (that is, both have an equatorial, or both have an axial, methoxyl group), and that the anomeric disposition for compound 2 is different. If the assignment previously made \[[@b6-jresv64an5p405_a1b]\] for the unacetylated relative of *any one of these three* acetylated glycosides is extended to its acetate, the conformations of the other two may be deduced from the results in [table 3](#t3-jresv64an5p405_a1b){ref-type="table"}. For example, if the anomeric group of methyl tri-*O*-acetyl-*β*-[d]{.smallcaps}-xylopyranoside is equatorial and that of its *α* anomer is axial, the results indicate that the anomeric group of methyl tri-*O*-acetyl-*β*-[l]{.smallcaps}-arabinopyranoside is axial. These conclusions are in complete agreement with the assignments previously made \[[@b6-jresv64an5p405_a1b]\] for the related unacetylated glycosides.

The corresponding bands of the methyl tri-*O*- acetyl-[d]{.smallcaps}-lyxopyranosides (compounds 7 and 8) are also given in [table 3](#t3-jresv64an5p405_a1b){ref-type="table"}. The results suggest that, for each anomer thereof, either (a) a conformation is adopted that is not a chair form and has a quasi, or a different kind of axial or equatorial, anomeric group, or (b) the crystalline material is a mixture of the CA and CE conformations. These conclusions agree with the previous findings for the unacetylated [d]{.smallcaps}-lyxopyranosides \[[@b6-jresv64an5p405_a1b]\].

5.2. Analysis of the Spectra of Groups of Configurationally Related, Acetylated Aldopyrano-sides, Excluding the Acetylated Aldopentopyranosides
-----------------------------------------------------------------------------------------------------------------------------------------------

As a test of the method of analysis, an examination was made of the spectra of methyl tetra-*O*-acetyl- *α*-[d]{.smallcaps}-gulopyranoside (compound 16), the anomers of methyl penta-*O*-acetyl [d]{.smallcaps}-*glycero*-[d]{.smallcaps}-*gulo*-heptopyranoside (17 and 18), and cyclohexyl penta-*O*-acetyl-[d]{.smallcaps}-*glycero-β*-[d]{.smallcaps}-*gulo*-heptopynmoside (19), because assignments of anomeric disposition had previously been made \[[@b6-jresv64an5p405_a1b]\] for the corresponding unacetylated glycosides. The results are given in [table 4](#t4-jresv64an5p405_a1b){ref-type="table"}, [3](#fn3-jresv64an5p405_a1b){ref-type="fn"} in which the anomer-differentiating bands shown by compounds 17 and 18 are compared with corresponding bands of compound 16 on the one hand and compound 19 on the other. Such bands, shown by two of the compounds (but not by the other two) are listed as follows: Column A, compounds 16 and 17, B, 16 and 18; C, 17 and 19; D, 18 and 19. It may be seen that compound 16 shows about equal similarity to either compound 17 or 18. In contrast, compound 17 has only one such band in common with compound 19, but compounds 18 and 19 have twelve such bands in common. If the assignment previously made for the unacetylated parent is extended to the acetate, for any one of the acetates 17, 18, or 19, the results are in accordance with the assignments previously made for all four parent glycosides. These are, for the anomeric group, as follows: Compound 17, axial; compounds 18 and 19, equatorial; and compound 16, quasi, or a different kind of axial or equatorial disposition, or a mixture of axial and equatorial forms.

As a further check on the results accruing from our method of analysis, a second group of acetylated glycosides (for whose parent glycosides assignments had previously been made \[[@b6-jresv64an5p405_a1b]\]) was studied. The results are given in [table 5](#t5-jresv64an5p405_a1b){ref-type="table"}: column A lists three bands shown by methyl tetra-(*O*-acetyl-*β*-[d]{.smallcaps}-galactopyranoside (compound 23) but not by compounds 21 and 22; column B lists eleven bands shown by methyl tri-*O*-acetyl-6-deoxy-*α*-[l]{.smallcaps}-galactopyranoside (compound 21) and by the *α* anomer, compound 22. Compounds 21 and 23 showed no anomer-differentiating bands in common. Consequently, if the assignment previously made for the unacetylated parent of *any one of these three compounds* is extended to the corresponding acetate, the assignments for the acetates are in harmony with those for the three parent glycosides. For the disposition of the anomeric group, these are as follows: Compounds 21 and 22, axial; and compound 23, equatorial.

All of the foregoing deductions are compatible with the concept that an acetylated glycoside adopts the same conformation as its parent (unacetylated) glycoside. Consequently, because of the agreement between the assignments previously made for the parent glycosides \[[@b6-jresv64an5p405_a1b]\] and now made for the acetylated glycosides, the utility of our empirical method for analyzing the spectra (and the validity of the deductions) was apparently established. The spectra of the remaining 12 glycosides were, therefore, examined. No assignment had previously been made as to the stable conformation of compounds 5, 6, 12, 13, 14, 15, and 24.

No assignment could be made for compound 5 (in comparison with compounds 3 and 4) because of the lack of the *α* anomer (with respect to the glycosidic methyl group) of compound 5. However, the anomer-differentiating bands for the anomers of methyl tetra-*O*-acetyl-[d]{.smallcaps}-glucopyranoside (compounds 3 and 4) are presented in [table 6](#t6-jresv64an5p405_a1b){ref-type="table"} for future use.

No assignment could be made for compound 6, because no other acetylated methyl aldopyranosides having the *ido* configuration were available for comparison. Similarly, no assignment could be made for compound 24, because of a lack of acetylated methyl aldopyranosides having the *altro* configuration.

Finally, assignments were sought for compounds 12 to 15; their spectra were compared with those of compounds 9 to 11 (for which we had previously made assignments for the unacetylated glycosides). First of all, the spectra of the anomers of methyl tri-*O*-acetyl-6-deoxy-[l]{.smallcaps}-maimopyranoside (compounds 9 and 10) were compared with those of the anomers of methyl tetra-*O*-acetyl-[d]{.smallcaps}-mannopyranoside (compounds 11 and 12). The results are given in [table 7](#t7-jresv64an5p405_a1b){ref-type="table"}; column A gives bands shown by compounds 9 and 11 (a anomers) but not by compounds 10 and 12 (*β* anomers), and column B records bands shown by the two *β* anomers but not by the *α* anomers. (Only one discrepancy was noted, namely, that compounds 10 and 11 show a band at 1,168--1,167 cm^−1^ that is absent from the spectra of compounds 9 and 12.) It may be concluded that, assuming the validity of the correlations, if the anomeric group of the *α* anomers is axial, that of the *β* anomers is equatorial, or *vice versa.* If the conformation assigned to the unacetylated parent of any one of three of these four compounds (9, 10, and 11) is accepted for its acetate, the deduced conformations for the other two are in agreement with those for the unacetylated compounds. Furthermore, the results indicate that methyl tetra-*O*-acetyl-*β*-[d]{.smallcaps}-mannopyranoside (compound 12) has an equatorial anomeric group.

The anomeric disposition of methyl penta-*O*- acetyl-[d]{.smallcaps}-*glycero-β*-[l]{.smallcaps}-*manno*-heptopyranoside (13) was now studied by a double comparison---against (a) the anomers of methyl tri-*O*-acetyl-6-deoxy-[l]{.smallcaps}-mannopyranoside, and (b) the anomers of methyl tetra-*O*-acetyl-[d]{.smallcaps}-mannopyranoside. The results are given in [table 8](#t8-jresv64an5p405_a1b){ref-type="table"}. Column A of [table 8](#t8-jresv64an5p405_a1b){ref-type="table"} records bands shown by compounds 9 and 13 but not by 10; column B gives bands shown by compound 9 but not by 10 and 13; column C gives bands shown by 10 and 13 but not by 9; column D gives bands shown by 11 and 13 but not by 12; column E gives bands shown by compound 11 but not by 12 and 13; and column I gives bands shown by 12 and 13 but not by 11. It is seen that, whereas the 16 bands in columns B and C indicate similarity between compounds 10 and 13, only two bands in column A suggest similarity of compounds 9 and 13. Similarly, whereas the 18 bands in columns E and F indicate similarity between compounds 12 and 13, only four bands in column D suggest similarity between compounds 11 and 13. Thus, a total of 34 bands indicate relationship of compound 13 to compounds 10 and 12 (as against a total of six bands indicating a relationship of compound 13 to compounds 9 and 11). These results suggest that the anomeric group of compound 13 is equatorial.

To obtain information regarding the disposition of the methoxyl group in the anomers of methyl hepta- *O*-acetyl-4-*O-β*-[d]{.smallcaps}-glucopyranosyl-[d]{.smallcaps}-marmopyranoside (compounds 14 and 15), the spectra of these compounds were compared with those of the anomers of methyl tetra-*O*-acetyl-[d]{.smallcaps}-mannopyranoside (compounds 11 and 12). The results are given in [table 9](#t9-jresv64an5p405_a1b){ref-type="table"}; column A records bands shown by compounds 11 and 14 (but not by compounds 12 and 15) ; column 13 gives the bands shown by compounds 12 and 15 (but not by compounds 11 and 14). If the assignments previously made for compounds 11 and 12 are accepted, these results indicate that the methoxyl group is axial in compound 14 and equatorial in compound 15.

For molecules as complex as those of the acetylated aldopyranosides, many of the observed bands cannot yet be assigned to particular vibrational modes. Thus, in sections 5.1 and 5.2, we have not been concerned with (a) which bands, arising from vibrations localized in a functional group, are relatively independent of the remainder of the molecule, or (b) which bands involve other parts of the molecule. However, in section 5.3, bands possibly attributable to specific functional groups are considered.

5.3. Other Absorption Bands
---------------------------

All of the compounds in this study are acetates, and their spectra all show at least one band (C=0 stretching frequency) at 1,764 to 1,736 cm^−1^ (except for compound 5, with a band at 1,773 cm^−1^); at 1,264 to 1,241 cm^−1^ (or at 1,259 to 1,239 cm^−1^); at 1,235 to 1,215 cm^−1^; at 667 to 632 cm^−1^; and at 614 to 585 cm^−1^. All of the spectra show at least one band at 2,994 to 2,941 cm^−1^ (C---H stretching); and at 1,462 to 1,445 cm^−1^ and 1,335 to 1,318 cm^−1^ (C---H bending). All of the spectra show an absorption band at 1,445 to 1,431 cm^−1^ and at 1,379 to 1,368 cm^−1^, presumably caused by deformation of the CH~3~ groups.

[Figure 1](#f1-jresv64an5p405_a1b){ref-type="fig"} gives the percentage of the 24 compounds in this study that show absorption bands in the various regions of the infrared spectrum; the cross- hatched areas in the region of 333 to 250 cm^−1^ correspond to the region marked, on certain spectra, with dashes. For the range of 5,000 to 2,000 cm^−1^, decrements of 20 cm^−1^ in wavenumber were used; and, for the range of 2,000 to 250 cm^−1^, decrements of 10 cm^−1^. [Figure 2](#f2-jresv64an5p405_a1b){ref-type="fig"} depicts the corresponding "profile" for 21 unacetylated glycosides, compiled from the spectra given in part II of this series \[[@b6-jresv64an5p405_a1b]\].

Compound 19, having a cyclohexyloxy group, showed bands at 2,941 and 2,865 cm^−1^, possibly characteristic of ---CH~2~--- (C---H stretching). It also showed bands at 1,451 and 1,435 cm^−1^, possibly attributable to ---CH~2~--- (C---H deformation).

All of the acetylated methyl aldopyranosides show a band in the range of 2,882 to 2,833 cm^−1^, excepting compound 4 (band at 2,915 cm^−1^). This band may possibly be attributable to the glycosidic methoxyl group, since Henbest and coworkers \[[@b12-jresv64an5p405_a1b]\] have observed that methoxyl groups absorb in the range of 2,832 to 2,819 cm^−1^. All of the acetylated methyl glycopyranosides also show bands at 1,374 to 1,325 cm^−1^, 1,259 to 1,241 cm^−1^, 1,148 to 1,114 cm^−1^, and 1,110 to 1,074 cm^−1^. A band near 1,100 cm^−1^ is characteristic \[[@b13-jresv64an5p405_a1b]\] of the methoxyl groups in methoxysteroids.

6. Experimental Procedures
==========================

6.1. Preparation and Purification of the Compounds
--------------------------------------------------

The compounds listed in [table 1](#t1-jresv64an5p405_a1b){ref-type="table"} were prepared by the methods given in the references cited. Most of the compounds were prepared in the course of an earlier study \[[@b14-jresv64an5p405_a1b]\] on the structural and configurational relationships of the anomers of the methyl pentopyranosides, hexopyranosides, and heptopyranosides. Each acetate was recrystallized from an appropriate solvent until further recrystallization caused no change in its melting point or optical rotation.

6.2. Preparation of the Pellets
-------------------------------

Samples for spectrophotometric study were prepared in the solid phase, as pellets consisting of the crystalline acetate suspended in an alkali-metal halide, exactly as previously described \[[@b11-jresv64an5p405_a1b]\]. For the range of 5,000 to 667 cm^−1^, a concentration of 0.4 mg of acetate per 100 mg of potassium chloride was used, except for compounds 5 (4 mg/100 mg) and 15 (0.8 mg/100 mg). For the range of 667 to 250 cm^−1^, a concentration of 2 mg of acetate per 100 mg of potassium iodide was used, except for compounds 5 (6 mg/100 mg) and 15 (3 mg/100 mg). Comparisons of intensity of absorption, from one compound to another, can only be true and quantitative where the molar concentration is the same.

6.3. Measurement of Infrared Absorption
---------------------------------------

The spectrograms are shown in [figures 3](#f3-jresv64an5p405_a1b){ref-type="fig"} and [4](#f4-jresv64an5p405_a1b){ref-type="fig"}. Those in [figure 3](#f3-jresv64an5p405_a1b){ref-type="fig"} for compounds 5 and 15 were recorded with a Beckman Model IR4 (double-beam) spectrophotometer equipped with prisms of sodium chloride. The others were recorded with a Perkin- Elmer Model 21 (double-beam) spectrophotometer equipped with a prism of sodium chloride (for the range of 5,000 to 667 cm^−1^) and of cesium bromide (for the range of 667 to 250 cm^−1^), as previously described \[[@b11-jresv64an5p405_a1b]\].

Some absorption attributable to water (in the compound, the alkali halide, or both) was observed at 3,448 and 1,639 cm^−1^ and, attributable to atmospheric water vapor, in the far-infrared curves. These regions are drawn on the spectrograms with dashed lines which merely indicate uncertainty and are not to be interpreted quantitatively.

6.4. Spectra Measured Under Different Conditions
------------------------------------------------

The spectra of 13 of the acetylated aldopyranosides (compounds 1 to 4, 7, 9 to 12, 18, 20, 22, and 23) had previously been measured \[[@b3-jresv64an5p405_a1b]\] in carbon tetrachloride and in either carbon disulfide, dioxane, or chloroform. As has previously been mentioned, the infrared absorption spectra of crystalline materials show more bands than the spectra of the same compounds in solution. As a result, a larger number of bands were available for correlations than in the previous study \[[@b3-jresv64an5p405_a1b]\].

The authors express their gratitude to Harriet L. Frush and J. D. Moyer for preparing and purifying many of the compounds used in this study, and to J. E. Stewart, J. J. Comeford, and F. P. Czech for recording the infrared absorption spectra.

Figures in brackets indicate the literature references at the end of this paper. The references for [table 1](#t1-jresv64an5p405_a1b){ref-type="table"} are given at the end of the table.

For comparison, bands (in about the same positions) shown by either or both anomers of methyl *tri-O-acetyl-[d]{.smallcaps}-lyxopyranoside* are also given in [table 2](#t2-jresv64an5p405_a1b){ref-type="table"}.

To conserve space, bands which do not differentiate between anomers havebeen omitted from [tables 4](#t4-jresv64an5p405_a1b){ref-type="table"} to [9](#t9-jresv64an5p405_a1b){ref-type="table"}.

![Percentage (of the 24 acetylated glycosides) which showed infrared absorption at the various regions of the infrared spectrum (5,000 to 250 cm^−1^).](jresv64an5p405_a1bf1){#f1-jresv64an5p405_a1b}

![Percentage (of the 21 unacetylated glycosides) which showed infrared absorption at the various regions of the infrared spectrum (5,000 to 250 cm^−1^).](jresv64an5p405_a1bf2){#f2-jresv64an5p405_a1b}

###### 

Spectrograms of materials in potassium chloride pellets.

**1**, Methyl *α*-[d]{.smallcaps}-xylopyranoside triacetate; **2**, methyl *β*-[d]{.smallcaps}-xylopyranoside triacetate; **3**, methyl *α*-[d]{.smallcaps}-glucopyranoside tetraacetate; **4**, methyl *β*-[d]{.smallcaps}-glucopyranoside tetraacetate.

**5**, methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→6)-*β*-[d]{.smallcaps}-glucopyranoside heptaacetate; **6**, methyl [d]{.smallcaps}-*glycero-β*(?)-[d]{.smallcaps}-*ido*-heptopyranoside pentaacetate; **7**, methyl *α*-[d]{.smallcaps}-lyxopyranoside triacetate; **8**, methyl *β*-[d]{.smallcaps}-lyxopyranoside triacetate.

**9**, methyl 6-deoxy-*α*-[l]{.smallcaps}-mannopyranoside triacetate; **10**, methyl 6-deoxy-*β*-[l]{.smallcaps}-mannopyranoside triacetate **11**, methyl *α*-[d]{.smallcaps}-mannopyranoside tetraacetate; **12**, methyl *β*-[d]{.smallcaps}-mannopyranoside tetraacetate.

**13**, methyl [d]{.smallcaps}-*glycero-β*-[l]{.smallcaps}-*manno*-heptopyranoside pentaacetate; **14**, methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*α*-[d]{.smallcaps}-mannopyranoside heptaacetate; **15**, methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*β*-[d]{.smallcaps}-mannopyranoside heptaacetate; **16**, methyl *α*-[d]{.smallcaps}-gulopyranoside tetraacetate.

**17**, methyl [d]{.smallcaps}-*glycero-α*-[d]{.smallcaps}-*gulo*-heptopyranoside pentaacetate; **18**, methyl [d]{.smallcaps}-*glycero-β*-[d]{.smallcaps}-*gulo*-heptopyranoside pentaacetate: **19**, cyclohexyl [d]{.smallcaps}-*glycero-β*-[d]{.smallcaps}-*gulo*-heptopyranoside pentaacetate; **20**, methyl *β*-[l]{.smallcaps}-arabinopyranoside triacetate.

**21**, methyl 6-deoxy-*α*-[l]{.smallcaps}-galactopyranoside triacetate; **22**, methyl *α*-[d]{.smallcaps}-galactopyranoside tetraacetate; **23**, methyl *β*-[d]{.smallcaps}-galactopyranoside tetraacetate; 24, methyl *β*-[d]{.smallcaps}-galactopyranosyl-(1→4)-*β*-[d]{.smallcaps}-altropyranoside heptaacetate.

![](jresv64an5p405_a1bf3)

![](jresv64an5p405_a1bf3a)

![](jresv64an5p405_a1bf3b)

![](jresv64an5p405_a1bf3c)

![](jresv64an5p405_a1bf3d)

![](jresv64an5p405_a1bf3e)

###### 

Spectrograms of materials in potassium iodide pellets.

**1**, Methyl *α*-[d]{.smallcaps}-xylopyranoside triacetate; **2**, methyl *β*-[d]{.smallcaps}-xylopyranoside triacetate; **3**, methyl *α*-[d]{.smallcaps}-glucopyranoside tetraacetate; **4**, methyl *β*-[d]{.smallcaps}-glucopyranoside tetraacetate.

**5**, methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→6)-*β*-[d]{.smallcaps}-glucopyranoside heptaacetate; **6**, methyl [d]{.smallcaps}-glycero-*β*(?)-[d]{.smallcaps}-ido-heptopyranoside pentaacetate; **7**, methyl *α*-[d]{.smallcaps}-lyxopyranoside triacetate; **8**, methyl *β*-[d]{.smallcaps}-lyxopyranoside triacetate.

**9**, methyl 6-deoxy-*α*-[l]{.smallcaps}-mannopyranoside triacetate; **10**, methyl 6-deoxy-*β*-[l]{.smallcaps}-mannopyranoside triacetate; **11**, methyl *α*-[d]{.smallcaps}-mannopyranoside tetraacetate; **12**, methyl *β*-[d]{.smallcaps}-mannopyranoside tetraacetate.

**13**, methyl [d]{.smallcaps}-glycero-*β*-[l]{.smallcaps}-manno-heptopyranoside pentaacetate; **14**, methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*α*-[d]{.smallcaps}-mannopyranoside heptaacetate; **15**, methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*β*-[d]{.smallcaps}-mannopyranoside heptaacetate; **16**, methyl *α*-[d]{.smallcaps}-gulopyranoside tetraacetate.

**17**, methyl [d]{.smallcaps}-glycero-*α*-[d]{.smallcaps}-gulo-heptopyranoside pentaacetate; **18**, methyl [d]{.smallcaps}-glycero-*β*-[d]{.smallcaps}-gulo-heptopyranoside pentaacetate; **19**, cyclohexyl [d]{.smallcaps}-glycero-*β*-[d]{.smallcaps}-gulo-heptopyranoside pentaacetate; **20**, methyl *β*-[l]{.smallcaps}-arabinopyranoside triacetate.

**21**, methyl 6-deoxy-*α*-[l]{.smallcaps}-galactopyranoside triacetate; **22**, methyl *α*-[d]{.smallcaps}-galactopyranoside tetraacetate; **23**, methyl *β*-[d]{.smallcaps}-galactopyranoside tetraacetate; 24, methyl *β*-[d]{.smallcaps}-galactopyranosyl-(1→4)-*β*-[d]{.smallcaps}-altropyranoside heptaacetate.

![](jresv64an5p405_a1bf4)

![](jresv64an5p405_a1bf4a)

![](jresv64an5p405_a1bf4b)

![](jresv64an5p405_a1bf4c)

![](jresv64an5p405_a1bf4d)

![](jresv64an5p405_a1bf4e)

###### 

Compounds measured, stable conformations, and index to spectrograms

  Code[a](#tfn1-jresv64an5p405_a1b){ref-type="table-fn"}   Compound                                                                                                                                               Reference                                                                                                    Stable conformation[b](#tfn2-jresv64an5p405_a1b){ref-type="table-fn"}   Spectrogram                                
  -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------- ------------------- ---------------------- ----
                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  12.11111(2,3,4)21                                        Methyl *α*-[d]{.smallcaps}-xylopyranoside, triacetate                                                                                                  [1](#tfn7-jresv64an5p405_a1b){ref-type="table-fn"}                                                           CA                                                                      CA                  *a*                    1
  12.11211(2,3,4)21                                        Methyl *β*-[d]{.smallcaps}-xylopyranoside, triacetate                                                                                                  [2](#tfn8-jresv64an5p405_a1b){ref-type="table-fn"}, [3](#tfn9-jresv64an5p405_a1b){ref-type="table-fn"}       CA                                                                      CA                  *e*                    2
  12.21111(2,3,4,6)21                                      Methyl *α*-[d]{.smallcaps}-glucopyranoside, tetraacetate                                                                                               [4](#tfn10-jresv64an5p405_a1b){ref-type="table-fn"} to [6](#tfn12-jresv64an5p405_a1b){ref-type="table-fn"}   CA                                                                      CA                  *a*                    3
  12.21211(2,3,4,6)21                                      Methyl *β*-[d]{.smallcaps}-glucopyranoside, tetraacetate                                                                                               [4](#tfn10-jresv64an5p405_a1b){ref-type="table-fn"}, [6](#tfn12-jresv64an5p405_a1b){ref-type="table-fn"}     CA                                                                      CA                  *e*                    4
  22.21?(2,3,4,6)21^\*^(1-6).21?11(2,3,4)21                Methyl *β*-[d]{.smallcaps}-glucopyranosyl-(l→6)-*β*-[d]{.smallcaps}-glucopyranoside, heptaacetate.[e](#tfn5-jresv64an5p405_a1b){ref-type="table-fn"}   [7](#tfn13-jresv64an5p405_a1b){ref-type="table-fn"}                                                          ..........                                                              ..........          ..........             5
  12.35?11(2,3,4,6,7)21                                    Methyl [d]{.smallcaps}-*glycero-β*(?)-[d]{.smallcaps}-*ido*-heptopyranoside, pentaacetate.                                                             [8](#tfn14-jresv64an5p405_a1b){ref-type="table-fn"}                                                          ..........                                                              ..........          ..........             6
                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  12.12511(2,3,4)21                                        Methyl *α*-[d]{.smallcaps}-lyxopyranoside, triacetate                                                                                                  [9](#tfn15-jresv64an5p405_a1b){ref-type="table-fn"},[10](#tfn16-jresv64an5p405_a1b){ref-type="table-fn"}     CA+CE; non-chair.                                                       CA+CE; non-chair.   *a+e; a,e,.* or *q.*   7
  12.12511(2,3,4)21                                        Methyl *β*-[d]{.smallcaps}-lyxopyranoside, triacetate                                                                                                  [11](#tfn17-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA+CE; non-chair.                                                       CA+CE; non-chair.   *a+e; a,e, or q.*      8
  12.22111(2,3,4)21(6)80                                   Methyl 6-deoxy-*α*-[l]{.smallcaps}-mannopyranoside, triacetate                                                                                         [12](#tfn18-jresv64an5p405_a1b){ref-type="table-fn"},[13](#tfn19-jresv64an5p405_a1b){ref-type="table-fn"}    CA                                                                      CA                  *a*                    9
  12.22211(2,3,4)21(6)80                                   Methyl 6-deoxy-*β*-[l]{.smallcaps}-mannopyranoside, triacetate                                                                                         [12](#tfn18-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA                                                                      CA                  *e*                    10
  12.22111(2,3,4,6)21                                      Methyl *α*-[d]{.smallcaps}-mannopyranoside, tetraacetate                                                                                               [14](#tfn20-jresv64an5p405_a1b){ref-type="table-fn"},[15](#tfn21-jresv64an5p405_a1b){ref-type="table-fn"}    CA                                                                      CA                  *a*                    11
  12.22211(2,3,4,6)21                                      Methyl *β*-[d]{.smallcaps}-mannopyranoside, tetraacetate                                                                                               [14](#tfn20-jresv64an5p405_a1b){ref-type="table-fn"},[15](#tfn21-jresv64an5p405_a1b){ref-type="table-fn"}    ..........                                                              CA                  *e*                    12
  12.42211(2,3,4,6,7)21                                    Methyl [d]{.smallcaps}-*glycero-β*-[l]{.smallcaps}-*manno*-heptopyranoside, pentaacetate.                                                              [11](#tfn17-jresv64an5p405_a1b){ref-type="table-fn"}                                                         ..........                                                              CA                  *e*                    13
  22.21?(2,3,4,6)21^\*^(1-4).22111(2,3,6)21                Methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*α*-[d]{.smallcaps}-mannopyranoside, heptaacetate.                                                     [16](#tfn22-jresv64an5p405_a1b){ref-type="table-fn"},[17](#tfn23-jresv64an5p405_a1b){ref-type="table-fn"}    ..........                                                              CA                  *a*                    14
  22.21?(2,3,4,6)21^\*^(1-4).22211(2,3,6)21                Methyl *β*-[d]{.smallcaps}-glucopyranosyl-(1→4)-*β*-[d]{.smallcaps}-mannopyranoside, heptaacetate.                                                     [16](#tfn22-jresv64an5p405_a1b){ref-type="table-fn"}                                                         ..........                                                              CA                  *e*                    15
  12.26511(2,3,4,6)21                                      Methyl *α*-[d]{.smallcaps}-gulopyranoside, tetraacetate                                                                                                [18](#tfn24-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA+CE; non-chair.                                                       CA+CE; non-chair.   *a+e; a,e*, or *q.*    16
  12.36111(2,3,4,6,7)21                                    Methyl [d]{.smallcaps}-*glycero-α*-[d]{.smallcaps}-*gulo*-heptopyranoside, pentaacetate.                                                               [11](#tfn17-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA                                                                      CA                  *a*                    17
  12.36211(2,3,4,6,7)21                                    Methyl [d]{.smallcaps}-*glycero-β*-[d]{.smallcaps}-*gulo*-heptopyranoside, pentaacetate.                                                               [19](#tfn25-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA                                                                      CA                  *e*                    18
  12.36213(2,3,4,6,7)21                                    Cyclohexyl [d]{.smallcaps}-*glycero-β*-[d]{.smallcaps}-*gulo*-heptopyranoside, pentaacetate.                                                           [20](#tfn26-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA                                                                      CA                  *e*                    19
                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  12.13311(2,3,4)21                                        Methyl *β*-[l]{.smallcaps}-arabinopyranoside, triacetate                                                                                               [21](#tfn27-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CE                                                                      CE                  *a*                    20
  12.23111(2,3,4)21(6)80                                   Methyl 6-deoxy-*α*-[l]{.smallcaps}-galactopyranoside, triacetate                                                                                       [22](#tfn28-jresv64an5p405_a1b){ref-type="table-fn"}                                                         CA                                                                      CA                  *a*                    21
  12.23111(2,3,4,6)21                                      Methyl *α*-[d]{.smallcaps}-galactopyranoside, tetraacetate                                                                                             [23](#tfn29-jresv64an5p405_a1b){ref-type="table-fn"}, [24](#tfn30-jresv64an5p405_a1b){ref-type="table-fn"}   CA                                                                      CA                  *a*                    22
  12.23211(2,3,4,6)21                                      Methyl *β*-[d]{.smallcaps}-galactopyranoside, tetraacetate                                                                                             [6](#tfn12-jresv64an5p405_a1b){ref-type="table-fn"}, [24](#tfn30-jresv64an5p405_a1b){ref-type="table-fn"}    CA                                                                      CA                  *e*                    23
  22.23?(2,3,4,6)21^\*^(1-4).27?11(2,3,6)21                Methyl *β*-[d]{.smallcaps}-galactopyranosyl-(l→4)-*β*-[d]{.smallcaps}-altropyranoside, heptaacetate.                                                   [25](#tfn31-jresv64an5p405_a1b){ref-type="table-fn"}                                                         ..........                                                              ..........          ..........             24

The third figure after the point was inserted after the present conclusions as to conformation had been reached.

Named by the system of H. S. Isbell and R. S. Tipson, Science **130**, 793 (1959); J. Research NBS **64A**, 171 (1960).

Assignment made by R. S. Tipson and H. S. Isbell, J. Research NBS **64A**, 239 (1960).

After accepting several of the assignments for the unacetylated glycosides (see text).

A sample of the original material, prepared by J. M. Johnson in November 1916, was kindly presented by N. K. Richtmyer.
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###### 

Bands (cm^−1^) shown by both anomers of methyl tri-*O*-acetyl-*[d]{.smallcaps}*-xylopyranoside (compounds 1 and 2) and by methyl tri-*O*-acetyl-*β*-*[l]{.smallcaps}*-arabinopyranoside (20), and positionally corresponding bands of the methyl tri-*O*-acelyl-*[d]{.smallcaps}*-lyxopyranosides (7 and 8)

  Methyl tri-*O*-acetyl-[d]{.smallcaps}-xylopyranosides       Methyl tri-*O*-acetyl-*β* -[l]{.smallcaps}-arabinopyranoside   Methyltri-*O*-acetyl-[d]{.smallcaps}-lyxopyranosides                                                                
  ----------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ------------------
                                                                                                                                                                                                                                                 
  Possibly non-configurational bands                                                                                                                                                                                                             
                                                                                                                                                                                                                                                 
  1745                                                        1742                                                           1739                                                      1736                                                      1733
  1456                                                        1462                                                           1453                                                      1462                                                      1456
  1441                                                        1443                                                           1445, 1437                                                1437                                                      1439
  1383                                                        1376                                                           1377                                                      1377                                                      1385
  1339                                                        1332                                                           1333                                                      1348                                                      1333
  1294                                                        1287                                                           1299                                                      1290                                                      1272
  1247                                                        1244                                                           1247                                                      1250                                                      1247
  1225                                                        1221                                                           1224                                                      1224                                                      1222
  1185                                                        1175                                                           1172                                                      1179                                                      1190
  1105                                                        1100                                                           1107                                                      1104                                                      1099
  [a](#tfn32-jresv64an5p405_a1b){ref-type="table-fn"}1075     [a](#tfn32-jresv64an5p405_a1b){ref-type="table-fn"}1075        [a](#tfn32-jresv64an5p405_a1b){ref-type="table-fn"}1068   1085                                                      1074
    885                                                         899                                                            895                                                       899                                                       889
    674                                                         689                                                            695                                                       690                                                       710
    586                                                         585                                                            578                                                       590                                                       596
    491                                                         499                                                            506                                                       498, 491                                                  491
    459                                                         458                                                            459, 447                                                  453                                                       453
    401                                                         399                                                            407                                                       408(?)                                                    399
    385                                                         392                                                            387                                                       382                                                       383
    376                                                         375                                                            378(?)                                                    376                                                       376
    344                                                         346                                                            345(?)                                                    332                                                       336(?), 332(?)
    292                                                          291(?)                                                        291(?)                                                    291(?)                                                    291(?)
                                                                                                                                                                                                                                                 
  Bands possibly affected by configuration and conformation                                                                                                                                                                                      
                                                                                                                                                                                                                                                 
  1473                                                        1477                                                           1468                                                      ...............                                           ...............
  1368                                                        1370                                                           ...............                                           1370                                                      1370
  1321                                                        1316                                                           ...............                                           1318                                                      1311
  1161                                                        1167                                                           ...............                                           ...............                                           ...............
  [b](#tfn33-jresv64an5p405_a1b){ref-type="table-fn"}1138     1129                                                           [b](#tfn33-jresv64an5p405_a1b){ref-type="table-fn"}1136   [b](#tfn33-jresv64an5p405_a1b){ref-type="table-fn"}1140   ...............
  1124                                                        1119                                                           ...............                                           ...............                                           ...............
  [a](#tfn32-jresv64an5p405_a1b){ref-type="table-fn"}1055     [b](#tfn33-jresv64an5p405_a1b){ref-type="table-fn"}1058        ...............                                           1060                                                      1064, 1057
  1044                                                        1040                                                           [a](#tfn32-jresv64an5p405_a1b){ref-type="table-fn"}1048   ...............                                           1045
  1031                                                        1024                                                           ...............                                           1027                                                      1024
  1013                                                        1003                                                           1006                                                      1014                                                      ...............
  984                                                         980                                                            ...............                                           980                                                       977
  ...............                                             ...............                                                ...............                                           963                                                       962
  [a](#tfn32-jresv64an5p405_a1b){ref-type="table-fn"}936      936                                                            938                                                       936                                                       ...............
  ...............                                             ...............                                                913                                                       917                                                       917
  904                                                         906                                                            902                                                       ...............                                           901
  877                                                         880                                                            877                                                       882                                                       ...............
  ...............                                             ...............                                                848                                                       856                                                       851
  648                                                         647                                                            ...............                                           638                                                       642
  619                                                         621                                                            626                                                       ...............                                           625
  600                                                         601                                                            601                                                       ...............                                           ...............
  551                                                         550                                                            ...............                                           ...............                                           ...............
  528                                                         527                                                            ...............                                           538                                                       517
  479                                                         475, 470                                                       482                                                       ...............                                           466
  ...............                                             ...............                                                418                                                       421                                                       413
  371                                                         370                                                            371(?)                                                    ...............                                           ...............
  317                                                         313                                                            ...............                                           310                                                       ...............

These bands were mentioned by R. L. Whistler and L. R. House \[[@b4-jresv64an5p405_a1b]\].

These bands were mentioned by H. S. Isbell and coworkers \[[@b3-jresv64an5p405_a1b]\].

###### 

Bands shown by only one anomer of the methyl tri-*O*-acetyl-*[d]{.smallcaps}*-xylopyranosides (compounds 1 and 2) and by methyl tri-*O*-acetyl-*β*-*[l]{.smallcaps}*-arabinopyranoside (20), compared with bands for both anomers of methyl tri-*O*-acetyl-*[d]{.smallcaps}*-lyxopyranoside (7 and 8)

  1                                                         20                                                        2               7                    8
  --------------------------------------------------------- --------------------------------------------------------- --------------- -------------------- -----------------
                                                                                                                                                           
  2933                                                      2941                                                      ..........      2941                 ..........
  2841                                                      2849                                                      ..........      2849                 ..........
  [a](#tfn34-jresv64an5p405_a1b){ref-type="table-fn"}1205   [a](#tfn34-jresv64an5p405_a1b){ref-type="table-fn"}1202   ..........      .........            1209
  949                                                         951                                                     ...........     ..........           949
  921                                                         926                                                     .........       ...........          ...........
  738                                                         757                                                     ...........     771                  755
  659                                                         660                                                     ...........     668                  665
  607                                                         612                                                     ..........      606                  608
  366                                                          365(?)                                                 ...........     ...........          ...........
  358                                                         359                                                     ............    .........            ............
  350                                                         350                                                     ............    ...........          351(?)
  263                                                          284(?)                                                 .............   ...........          ............
  ...........                                               ..........                                                3012            .............        ............
  ...........                                               ...........                                               2967            .............        2967
  ...........                                               ...........                                               2890            2899                 ...............
  ...........                                               ..........                                                2874            ............         2865
  ...........                                               ...........                                               1754            ..........           1745
  ............                                              ...........                                               1403            1399                 ............
  ...........                                               ............                                              1256            ............         ...........
  ..........                                                ............                                              ...........     1233                 ............
  ...........                                               ...........                                               1155            ............         1148
  ............                                              ............                                              992             ..................   ...............

See footnote b of [table 2](#t2-jresv64an5p405_a1b){ref-type="table"}.

###### 

Comparison[a](#tfn35-jresv64an5p405_a1b){ref-type="table-fn"} of absorption bands (cm^−1^) shown by methyl tetra-*O*-acetyl-*α*-*[d]{.smallcaps}*-gulopyranoside (compound 16), the anomers of methyl penla-*O*-acetyl-*[d]{.smallcaps}*-glycero-*[d]{.smallcaps}*-gulo-heptopyranoside (17 and 18), and cyclohexyl penta-*O*-acetyl-*[d]{.smallcaps}*-glycero-*β*-*[d]{.smallcaps}*-gulo-heptopyranoside (19)

  A      B      C        D                           
  ------ ------ -------- -------- ----- ----- ------ ------
                                                     
  2841   2849   1736     1745     831   825   2882   2865
  1414   1385      943      943               1745   1739
  1110   1110   650      649                  1282   1274
  818    831                                  1241   1242
                                              943    942
                                              858    864
                                              649    645
                                              508    506
                                              472    473
                                              459    459
                                              445    443
                                              341    341

Key: A. Bands shown by compounds 16 and 17, but not by 18. B. Bands shown by compounds 16 and 18, but not by 17. C. Bands shown by compounds 17 and 19, but not by 18. D. Bands shown by compounds 18 and 19, but not by 17.

###### 

Comparison [a](#tfn36-jresv64an5p405_a1b){ref-type="table-fn"} of absorption bands (cm^−1^) shown by the anomers of methyl tetra-*O*-acetyl-*[d]{.smallcaps}*-galactopyranoside (compounds 22 and 23) and by methyl tri-*O*-acelyl-6-deoxy-*α*-*[l]{.smallcaps}*-galaclopyranoside (21)

  A                                                          B       
  ---------------------------------------------------------- ------- ----------------------------------------------------------
                                                                     
  1014                                                       2933    2941
    [b](#tfn37-jresv64an5p405_a1b){ref-type="table-fn"}880   1215    1217
    611                                                      1200    [c](#tfn38-jresv64an5p405_a1b){ref-type="table-fn"}1190
                                                             1133    [c](#tfn38-jresv64an5p405_a1b){ref-type="table-fn"}1134
                                                             1049    1041
                                                               941     [b](#tfn37-jresv64an5p405_a1b){ref-type="table-fn"}949
                                                               928     [b](#tfn37-jresv64an5p405_a1b){ref-type="table-fn"}936
                                                               817     [b](#tfn37-jresv64an5p405_a1b){ref-type="table-fn"}821
                                                               759     [b](#tfn37-jresv64an5p405_a1b){ref-type="table-fn"}758
                                                               696     712
                                                               487     490

Key: A. Bands shown by compound 23, but not by compounds 21 and 22. B. Bands shown by compounds 21 and 22, but not by 23.

These bands were mentioned by S. A. Barker and coworkers \[[@b5-jresv64an5p405_a1b]\].

See footnotes a and b to [table 2](#t2-jresv64an5p405_a1b){ref-type="table"}.

###### 

Bands (cm^−1^) differentiating between the anomers of methyl ietra-*O*-acetyl-*[d]{.smallcaps}*-glucopyranoside (compounds 3 and 4)

  3(*α*)         4(*β*)
  -------------- ----------------------------------------------------------
                 
  2865           ............
  1241           ............
  1078           ............
    933          ............
    888          ............
    761          ............
    663          ............
    516          ............
    321          ............
  ............   2915
  ............   1318
  ............     [a](#tfn39-jresv64an5p405_a1b){ref-type="table-fn"}918
  ............     [a](#tfn39-jresv64an5p405_a1b){ref-type="table-fn"}873
  ............     537(?)
  ............    529

See footnote b to [table 5](#t5-jresv64an5p405_a1b){ref-type="table"}.

###### 

Comparison [a](#tfn40-jresv64an5p405_a1b){ref-type="table-fn"} of absorption bands (cm^−1^) shown by the methyl tri-*O*-acetyl-6-deoxy-*[l]{.smallcaps}*-mannopyranosides (compounds 9 and 10) and by the methyl tetra-*O*-acelyl-*[d]{.smallcaps}*-mannopyranosides (11 and 12)

  A                                                                                                                B                                                                   
  ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- --------- ---------------------------------------------------------
                                                                                                                                                                                       
  1443                                                                                                             1443                                                      1410      1404
  [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"}884                                                           [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"}886    1076      1074
  [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"} 837                                                          [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"} 832   867       [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"} 867
  [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"}797, [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"}791   [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"}792    752       [b](#tfn41-jresv64an5p405_a1b){ref-type="table-fn"}752
  685                                                                                                              690                                                       724       723
  614                                                                                                              616                                                       412,406   408
  514                                                                                                              510                                                                 

Key: A. Bands shown by compounds 9 and 11, but not by compounds 10 and 12. B. Bands shown by compounds 10 and 12, but not by compounds 9 and 11.

See footnote b to [table 5](#t5-jresv64an5p405_a1b){ref-type="table"}.

###### 

Comparison [a](#tfn42-jresv64an5p405_a1b){ref-type="table-fn"} of absorption bands (cm^−1^) shown by the methyl tri-*O*-acetyl-6-deoxy-*[l]{.smallcaps}*-mannopyranosides (compounds 9 and 10), the methyl tetra-*O*-acetyl-*[d]{.smallcaps}*-mannopyranosides (11 and 12), and methyl penta-*O*-acetyl-*[d]{.smallcaps}*-glycero-*β*-*[l]{.smallcaps}-manno*-heptopyrano side (13)

  A                                                        B     C                                                                                                                D          E          F                                                                                                                                                                                 
  -------------------------------------------------------- ----- ---------------------------------------------------------------------------------------------------------------- ---------- ---------- -------------------------------------------------------- ------ -------------------------------------------------------- -------------------------------------------------------- --------------
                                                                                                                                                                                                                                                                                                                                                                                          
  [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}837   829   1443                                                                                                             1410       1410(?)    1227                                                     1232   1443                                                     1404                                                     1410(?)
  495                                                      499   [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}884                                                           1168       1167       1167                                                     1167   1086                                                     1151                                                     1147    
                                                                 [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}797, [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}791   1076       1073       [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}832   829    1040                                                     1074                                                     1073    
                                                                 685                                                                                                              894        894        465(?)                                                   462    [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}886   [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}952   947    
                                                                 614                                                                                                              867        867                                                                        [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}792   [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}867   867    
                                                                 514                                                                                                              752        768                                                                        690                                                      [b](#tfn43-jresv64an5p405_a1b){ref-type="table-fn"}752   768    
                                                                                                                                                                                  724        725, 713                                                                   510                                                      723                                                      725, 713    
                                                                                                                                                                                  487        489                                                                                                                                 595                                                      596    
                                                                                                                                                                                  447        447                                                                                                                                 484                                                      476    
                                                                                                                                                                                  412, 406   409                                                                                                                                 408                                                      409    
                                                                                                                                                                                                                                                                                                                                 342(?)                                                   341    

Key: A. Bands shown by compounds 9 and 13, but not by 10. B. Bands shown by compound 9, but not by 10 and 13. C. Bands shown by compounds 10 and 13, but not by 9. D. Bands shown by compounds 11 and 13, but not by 12. E. Bands shown by compound 11, but not by 12 and 13. F. Bands shown by compounds 12 and 13, but not by 11.

See footnote b to [table 5](#t5-jresv64an5p405_a1b){ref-type="table"}.

###### 

Comparison[a](#tfn44-jresv64an5p405_a1b){ref-type="table-fn"} of absorption bands (cm^−1^) shown by the methyl tetra-*O*-acetyl-*[d]{.smallcaps}*-mannopyranosides (compounds 11 and 12) and by the methyl hepla-*O*-acetyl-4-*O*-*β*-*[d]{.smallcaps}*-glucopyranosyl-*[d]{.smallcaps}*-mannopyr ano sides (14 and 15)

  A                                                          B                                                                  
  ---------------------------------------------------------- ------- ---------------------------------------------------------- -------
                                                                                                                                
  1086                                                       1083    1010                                                       1003
    978                                                        976     [b](#tfn45-jresv64an5p405_a1b){ref-type="table-fn"}952     952
    [b](#tfn45-jresv64an5p405_a1b){ref-type="table-fn"}792     803     [b](#tfn45-jresv64an5p405_a1b){ref-type="table-fn"}904     904
    690                                                        693     [b](#tfn45-jresv64an5p405_a1b){ref-type="table-fn"}752     750
    616                                                        614     723                                                        731
    559                                                        557     570                                                        567

Key: A. Bands shown by compounds 11 and 14, but not by 12 and 15. B. Bands shown by compounds 12 and 15, but not by 11 and 14.

See footnote b to [table 5](#t5-jresv64an5p405_a1b){ref-type="table"}.
